· Primary endpoint of reducing annualized relapse rate was not statistically
· Following a standard adjustment, in accordance with a pre-defined sensitivity
analysis, laquinimod significantly reduced the annualized relapse rate (p=0.026)
· Laquinimod also demonstrated significant reductions in both brain volume loss
and the risk of disability progression, while maintaining a favorable safety and
tolerability profile
· Regulatory submissions are planned in the U.S. and EU
· Teva to host conference call to discuss study results on August 1, 8:30 a.m.

Jerusalem,  Israel  and  Lund,  Sweden,  August  1, 2011 -  Teva  Pharmaceutical
Industries  Ltd. (NASDAQ:  TEVA) and  Active Biotech  (NASDAQ OMX  NORDIC: ACTI)
announced  today  initial  results  from  the  Phase  III BRAVO study, which was
designed  to evaluate the  efficacy, safety and  tolerability of oral laquinimod
compared  to placebo  and to  provide a  benefit-risk assessment  comparing oral
laquinimod  and a  reference arm  of injectable  Interferon beta-1a (Avonex(®)).
BRAVO is the second of two pivotal Phase III studies in the clinical development
program  for laquinimod,  an investigational,  oral, once-daily  therapy for the
treatment of relapsing-remitting multiple sclerosis (RRMS).  Results showed that
the  BRAVO study did not achieve its primary endpoint of reducing the annualized
relapse rate (p=0.075).

The  randomization process for BRAVO  was adequately performed; however, placebo
and  treatment  study  groups  showed  dissimilarity  in  two  baseline magnetic
resonance  imaging  (MRI)  characteristics.  According  to  a  standard and pre-
specified sensitivity analysis included within the original statistical analysis
plan,  when this imbalance  was corrected laquinimod  demonstrated a significant
reduction  in  the  annualized  relapse  rate  (21.3%,  p=0.026), in the risk of
disability  progression as measured  by Expanded Disability  Status Scale (EDSS)
(33.5%, p=0.044) and in brain volume loss (27.5%, p<0.0001).

The  BRAVO  findings  support  the  direct  effect  of laquinimod in the central
nervous  system (CNS) and are  in line with the  results of the first laquinimod
Phase  III trial, ALLEGRO.   Additionally, as in  ALLEGRO, the BRAVO study found
that  laquinimod  demonstrated  a  favorable  safety  and  tolerability  profile
compared to placebo.

Compared  to  placebo,  treatment  with  Interferon  beta-1a reduced  annualized
relapse  rates; however, a  reduction in brain  tissue loss was not demonstrated
and a reduction in the progression of disability was not significant.

The  BRAVO study was  not designed to  provide direct statistical comparisons of
efficacy endpoints between the two active arms.

"We  are encouraged by the overall outcomes achieved in the laquinimod Phase III
clinical  development program,  and plan  to submit  applications  to regulatory
authorities  in the U.S. and EU," said Professor Yitzhak Peterburg, Teva's Group
Vice  President,  Global  Branded  Products.   "Teva  remains  committed  to the
clinical  development of laquinimod and is confident that the drug could provide
a unique option for the treatment of multiple sclerosis."

"Data from the ALLEGRO and BRAVO studies demonstrated that laquinimod reduced
disability and brain tissue loss, two of the most important goals in the
treatment of relapsing forms of multiple sclerosis," said Professor Per Soelberg
Sørensen, MD, Head of MS Research Unit, Copenhagen University Hospital,
Rigshospitalet, Co-principal investigator of the BRAVO study. "These effects,
coupled with a favorable safety profile and a once-daily dosing regimen create a
promising potential treatment for the disease."

Additional analyses of the BRAVO study data are ongoing, and results will be
submitted for presentation at a scientific congress later in the year.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host an audio webcast on
August 1, 2011 at 8:30 a.m. EDT to discuss the results from the Phase III BRAVO
study of laquinimod. Those interested in listening to the webcast should log on
to register for the event (approximately
10 minutes before). The dial-in for this call is 1-800-299-6183 or 617-801-9713
internationally. The conference ID or passcode is 85409706. An archive of the
webcast will be available on Teva's website.

BRAVO was a two-year, multi-national, multi-center, randomized, double-blind,
parallel-group, placebo-controlled study designed to compare the safety,
efficacy and tolerability of a once-daily oral dose of 0.6 mg laquinimod over
placebo and to provide a descriptive comparison of the risk-benefit profiles of
laquinimod and interferon beta-1a. The primary outcome measure was to assess the
efficacy of 0.6 mg daily dose of laquinimod as measured by the relapse rate.
Secondary outcome measures included impact on the accumulation of disability and
brain atrophy.  The BRAVO study completed enrollment in June 2009, recruiting
more 1,331 patients at 153 sites worldwide, including in the U.S., Europe,
Russia, Israel and South Africa.

Laquinimod is an oral, once-daily immunomodulator with a novel mechanism of
action being developed for the treatment of MS. The global Phase III clinical
development program evaluating oral laquinimod in MS consists of two pivotal
studies, ALLEGRO and BRAVO. In the ALLEGRO study, laquinimod demonstrated a
significant positive impact on disease activity, disability progression and MRI
measures of inflammation and neurodegeneration, while maintaining a favorable
safety and tolerability profile.  Specifically, laquinimod showed a
statistically significant 23 percent reduction in annualized relapse rate and
36 percent significant reduction in the risk of confirmed disability
progression, as measured by EDSS.

In  addition to  the MS  clinical studies,  laquinimod is  currently in Phase II
development  for  Crohn's  disease  and  Lupus,  and  is  being studied in other
autoimmune diseases.

MS is the leading cause of neurological disability in young adults. It is
estimated that more than 400,000 people in the United States are affected by the
disease and that two million people may be affected worldwide. Multiple
sclerosis is a degenerative disease of the central nervous system in which
inflammation and axonal damage and loss result in the development of progressive

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's largest generic drug
maker, with a global product portfolio of more than 1,300 molecules and a direct
presence in about 60 countries. Teva's branded businesses focus on neurological,
respiratory and women's health therapeutic areas as well as biologics. Teva
currently employs approximately 42,000 people around the world and reached $16.1
billion in net sales in 2010.

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in or entering
pivotal phase are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ for
prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily
of renal cell cancer. In addition, laquinimod is in Phase II development for
Crohn's and Lupus. Further projects in clinical development comprise the two
orally administered compounds, 57-57 for SLE & Systemic Sclerosis and RhuDex(TM)
for RA. Please visit www.activebiotech.comfor more information.

Teva's  Safe  Harbor  Statement  under  the  U. S. Private Securities Litigation
Reform Act of 1995:
The  statements, analyses and other information contained herein relating to the
completed  acquisition and its  effects on financial  and operating performance,
including estimates for growth, anticipated positions in the Japanese market and
shares  in  such  market,  the  market  for  Taiyo's  products, trends in Taiyo'
operating  and financial results,  the future development  and operation of Teva
and  Taiyo's businesses, and  the contingencies and  uncertainties to which Teva
and  Taiyo may be subject,  as well as other  statements including words such as
"anticipate,"   "believe,"   "plan,"  "estimate,"  "expect,"  "intend,"  "will,"
"should,"  "may" and other similar expressions, are "forward-looking statements"
under  the Private Securities Litigation Reform Act of 1995. Such statements are
made  based upon management's current expectations and beliefs concerning future
events  and their potential effects on the company and involve a number of known
and  unknown  risks  and  uncertainties  that  could  cause  our future results,
performance   or   achievements   to  differ  significantly  from  the  results,
performance  or  achievements  expressed  or  implied  by  such  forward-looking
statements. Actual results may differ materially from the results anticipated in
these   forward-looking  statements.  Important  factors  that  could  cause  or
contribute to such differences include whether and when the proposed acquisition
will  be consummated and the terms of  any conditions imposed in connection with
such  closing, our ability  to rapidly integrate  Taiyo's operations and achieve
expected  synergies, diversion of management  time on merger-related issues, our
ability  to  predict  future  market  conditions  with  accuracy, our ability to
develop  and commercialize additional pharmaceutical products, the difficulty of
complying   with  Pharmaceutical  and  Medical  Device  Agency-Japan  and  other
regulatory   authority   requirements,  competition  from  the  introduction  of
competing   generic  equivalents  and  due  to  increased  governmental  pricing
pressures,  the  effects  of  competition  on  sales of our innovative products,
especially  Copaxone® (including competition from innovative orally-administered
alternatives as well as from potential generic equivalents), potential liability
for  sales of generic products prior to a final resolution of outstanding patent
litigation,  including that  relating to  the generic  version of Protonix®, the
extent  to which we  may obtain U.S.  market exclusivity for  certain of our new
generic  products,  the  extent  to  which  any manufacturing or quality control
problems  damage our reputation  for high quality  production and require costly
remediation,  our  ability  to  identify,  consummate and successfully integrate
acquisitions  (including the  acquisition of  Cephalon), our  ability to achieve
expected   results  through  our  innovative  R&D  efforts,  dependence  on  the
effectiveness  of  our  patents  and  other protections for innovative products,
intense  competition in  our specialty  pharmaceutical businesses, uncertainties
surrounding  the  legislative  and  regulatory  pathway for the registration and
approval  of  biotechnology-based  products,  our  potential exposure to product
liability  claims to the extent not covered by insurance, any failures to comply
with  the complex Medicare  and Medicaid reporting  and payment obligations, our
exposure  to currency fluctuations and restrictions as well as credit risks, the
effects  of  reforms  in  healthcare  regulation  and pharmaceutical pricing and
reimbursement,  adverse effects  of political  or economical  instability, major
hostilities  or  acts  of  terrorism  on  our  significant worldwide operations,
increased government scrutiny in both the U.S. and Europe of our agreements with
brand  companies,  interruptions  in  our  supply  chain  or  problems  with our
information  technology systems that adversely  affect our complex manufacturing
processes,  the  impact  of  continuing  consolidation  of  our distributors and
customers,  the difficulty of complying with  U.S. Food and Drug Administration,
European   Medicines   Agency   and  other  regulatory  authority  requirements,
potentially significant impairments of intangible assets and goodwill, potential
increases  in  tax  liabilities  resulting  from  challenges to our intercompany
arrangements,  the  termination  or  expiration  of governmental programs or tax
benefits, any failure to retain key personnel or to attract additional executive
and  managerial talent, environmental risks and other factors that are discussed
in our filings with the SEC.

Active Biotech's Safe Harbor Statement in Accordance with the Swedish Securities
Market Act:
This press release contains certain forward-looking statements. Such forward-
looking statements involve known and unknown risks, uncertainties and other
important factors that could cause the actual results, performance or
achievements of the company, or industry results, to differ materially from any
future results, performance or achievement implied by the forward-looking
statements. The company does not undertake any obligation to update or publicly
release any revisions to forward-looking statements to reflect events,
circumstances or changes in expectations after the date of this press release.

Active Biotech is required under the Financial Instruments Trading Act to make
the information in this press release public. The information was submitted for
publication at 2:00 p.m. CET on August 1, 2011.


This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE